

Instruction of Disclosure of COI at JCA Meetings/Conferences

At JCA Meetings/Conferences, the lead presenter, the responsible researcher and Chair of the session, their spouse, family related in the first degree, or people who share income/property with them must declare and disclose their COIs (the “responsible researcher” in general denotes persons such as the Principle Investigator of the research laboratory or the Corresponding Author in the case of submission of an original research paper to a journal). In accordance with ["JCA Conflict of Interest Policy in Cancer Research"](#), please disclose COIs. JCA may penalize the presenters in the event of failure to disclose COI, in accordance with its disciplinary code.

Standards of Declaration and Disclosure

1. Existence or otherwise of position as **an officer of or an advisor (including consultant, etc.)** to companies or for-profit organizations (hereinafter the “Companies, etc.”) shall be declared if the annual value of remuneration from a single Company etc. is 1 million yen or more. If any of the declarer’s Relatives, etc. is an employee of the Companies, etc., this shall also be declared.
2. Ownership of **equities (such as shares and stock options)** and profit obtained from those equities shall be declared if the annual value of profit on shares of a single Company, etc. (total sum of dividends and proceeds from the sale of shares) is 1 million yen or more, or the proportion of shares owned in the Company, etc. is 5% or more. Ownership of stock options and so on shall be declared if latent profit from them is 1 million yen or more.
3. **Patent royalties or transfer gains** by the Companies, etc. shall be declared if the annual total value received from a single Company, etc. is 1 million yen or more.
4. Lecture fees, honoraria, or other fees paid by the Companies, etc. for the time or labor of a researcher engaged for **conference attendance (as a lecturer, chairperson, ad hoc advisor, etc.)** shall be declared if the annual total value received from a single Company, etc. is 500,000 yen or more.
5. Manuscript fees paid by the Companies etc. for **the writing of pamphlets, etc.** shall be declared if the annual total value received from a single Company, etc. is 500,000 yen or more.
6. **Research funds (such as contracted research funds, joint research funds, and clinical trial funds) provided under contract** by the Companies, etc. or by non-profit organizations funded by the Companies, etc. shall be declared if annual total amounts of direct cost paid from a single Company, etc. or organization to the declarer is 1 million yen or more. If the declarer personally receives any consideration from the Companies, etc., it shall be declared separately.
7. **Scholarship (incentive) endowments** provided from the Companies, etc. or **research grants provided from a private academic support organization** shall be declared if a total of 1 million yen or more per year is allocated as direct cost from such funds from a single Company, etc. or organization to an individual declarer or the department (lecture/area of specialization etc.) or research facility an individual declarer belongs to, with substantial control over its use given to that individual.
8. **An endowed chair etc.** funded by the Companies, etc. shall be declared if the declarer is affiliated with the chair. **A researcher, etc.** sent or provided by the Companies, etc. shall be declared if the declarer is the representative of the research facility with which the **researcher, etc.** is affiliated, regardless of whether or not employment costs for the researcher, etc. have been accepted.
9. **Fees of testimony, judgment, comment, etc. from:**
If you have earned more than 1 million yen per year as a fee for expert comment, judgment or testimony in legal proceedings, etc. from a company and/or a profit-making organization related to medicine these past three years, please specify the name of the company and/or an organization. It is equivalent if its ordered from the court.
10. **Any other remuneration (travel expenses, gifts, etc., that are not directly related to research)** shall be declared if the annual value of such remuneration received from a single Company, etc. is 50,000 yen or more.
11. **Representative of organization for clinical study receiving research expenses from:** If you are a representative of an organization for clinical study which receives research

expenses (donation, contract, others, and expenses for basic research are also subject to disclosure) from a profit-making/non-profit organization related to medicine, please specify the name of the company and/or organization.

12. **Research Funding: For all research funding related to the presentation topic—**including public funds such as MEXT/JSPS KAKENHI or AMED Research and Development grants, in addition to the research funds, donations, and grants mentioned above(No6 & 7)—disclose the names of the companies or organizations involved, regardless of the amount.

How to disclose your COI

- Oral presentation: If there is any COI, the oral presenter should use the disclosure slide to present COI after the title slide, in order to clarify the names of companies and/or associations in question. If there is no COI, the presenter should indicate 'I/We have no financial relationships to disclose.' as such on the sample slide.
- Poster presentation: If there is any COI, the poster presenter should disclose the names of companies and/or associations in question at the bottom area of the poster. If there is no COI, the presenter should indicate 'I/We have no financial relationships to disclose.' as such on the sample slide.

(Officers/employees of companies)

Please indicate the name of the company in the presentation documents. You do not need to disclose COI (however, if there is any COI with companies other than your own company, please declare it).

COI disclosure slide samples

If the lead presenter is the responsible researcher, choose the sample slide 1. If the lead presenter is NOT the responsible researcher, choose the sample slide 2 and prepare each COI disclosure slide on behalf of the responsible researcher.

- 1) Lead presenter is the responsible researcher



[COI Sample 1.pptx](#)

- 2) Lead presenter is NOT the responsible researcher



[COI Sample 2.pptx](#)

- 3) Chair



[COI Sample chair.pptx](#)

For inquiries concerning COI
Japanese Cancer Association Executive Office
E-mail: jca.office@imic.or.jp

COI declaration and disclosure
https://www.cancer.or.jp/modules/en/index.php?content_id=12